Core Insights - Lifecore Biomedical (LFCR) is anticipated to report a year-over-year increase in earnings driven by higher revenues for the quarter ended August 2025, with the consensus outlook indicating a significant impact on the stock price based on actual results compared to estimates [1][12] Earnings Expectations - The consensus EPS estimate for Lifecore Biomedical is a loss of $0.09 per share, which reflects a year-over-year change of +43.4%, while revenues are expected to reach $26.68 million, marking an 8% increase from the previous year [3] - The Most Accurate Estimate for Lifecore Biomedical is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -3.33%, indicating a bearish sentiment among analysts regarding the company's earnings prospects [12] Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 21.43% higher, suggesting a reassessment of initial estimates by covering analysts [4] - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3, with research indicating that this combination leads to a positive surprise nearly 70% of the time [10] Historical Performance - Lifecore Biomedical has only beaten consensus EPS estimates once in the last four quarters, with the most recent quarter showing a surprise of -11.11% as the company reported a loss of -$0.10 per share against an expected loss of -$0.09 [13][14] Conclusion - Lifecore Biomedical does not currently appear to be a compelling candidate for an earnings beat, and investors are advised to consider other factors when making decisions regarding the stock ahead of its earnings release [17]